Bibliografia

Al-Sawaf O, Zhang C, Lu T et al. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized LLC14 Study. J Clin Oncol 2021;39(36):4049-4060.

Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H et al. iwLLC guidelines for diagnosis, indications for treatment, response assessment, and supportive management of LLC. Blood 2018;131:2745–60.

Jain N, Keating M, Thompson P et al. Ibrutinib and Venetoclax for First-Line Treatment of LLC. N Engl J Med 2019;380(22):2095-2103.

Seymour JF, Kipps TJ, Eichhorst BF et al. Enduring undetectable MRD and updated outcomes in relapsed/refractory LLC after fixed-duration venetoclax-rituximab. Blood 2022;140(8):839-850.

Wang XV, Hanson CA, Tschumper RC et al. Measurable residual disease does not preclude prolonged progression-free survival in LLC treated with ibrutinib. Blood 2021;138(26):2809-2826.

Wierda WG, Rawstron A, Cymbalista F, Badoux X, Rossi D, Brown JR et al. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations. Leukemia 2021;35:3059–72.

Yang S, Kay NE, Shi M, Hanson CA, Gale RP. Is unmeasurable residual disease (uMRD) the best surrogate endpoint for clinical trials, regulatory approvals and therapy decisions in chronic lymphocytic leukaemia (LLC)? Leukemia 2022;36:2743-2747.

Rawstron AC, Davies FE, DasGupta R et al. Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100(9):3095-100 doi: 10.1182/ blood-2001-12-0297.

Kumar S, Paiva B, Anderson KC et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 2016;17(8):e328-e346 doi: 10.1016/S1470-2045(16)30206-6.

Cavo M, San-Miguel J, Usmani SZ. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood 2022;139(6):835844 doi: 10.1182/blood.2021011101.

Hermine O, Hoster E, Walewski J et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016;388(10044):565-75 doi: 10.1016/S01406736(16)00739-X.

Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012;367(6):520-31 doi: 10.1056/NEJMoa1200920.

Pott C, Hoster E, Delfau-Larue MH et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115(16):3215-23 doi: 10.1182/blood-2009-06-230250.

Ferrero S, Grimaldi D, Genuardi E et al. Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. Blood 2022;140(12):1378-1389 doi: 10.1182/blood.2021014270.

Luminari S, Manni M, Galimberti S et al. Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. J Clin Oncol 2022;40(7):729-739 doi: 10.1200/JCO.21.01234.

Ladetto M, Ferrero S, Del Giudice I et al. A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. Blood 2021;138(Supplement 1):41 https://doi.org/10.1182/blood-2021-146773.

Cordero F, Ferrero S, Pernice S et al. Dissecting MRD Kinetics By Automated Computational Analysis to Improve Outcome Prediction in Mantle Cell Lymphoma: A Bioinformatic Substudy from the Fondazione Italiana Linfomi (FIL) MCL0208 Clinical Trial. Poster #4220, ASH 2022.

Andersen NS, Pedersen LB, Laurell A et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009;27(26):4365-70 doi: 10.1200/JCO.2008.21.3116.

Le Gouill S, Thieblemont C, Oberic L et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med 2017;377(13):1250-1260 doi: 10.1056/ NEJMoa1701769.

Callanan MB, Macintyre E, Delfau-Larue MH et al. Predictive Power of Early, Sequential MRD Monitoring in Peripheral Blood and Bone Marrow in Patients with Mantle Cell Lymphoma Following Autologous Stem Cell Transplantation with or without Rituximab Maintenance; Final Results from the LyMa-MRD Project, Conducted on Behalf of the Lysa Group. Blood 2020;136(Supplement 1):12-13 https://doi.org/10.1182/ blood-2020-140457.

Delfau MH, Macintyre EA, Callanan MB et al. Impact of Maintenance Arm on Prognostic Value of MRD after Induction Treatment in MCL R2 Elderly Trial, a Mantle Cell Lymphoma Network Study. Blood 2021;138(Supplement 1):40 https://doi. org/10.1182/blood-2021-145288.

van der Velden VHJ, Panzer-Grümayer ER, Cazzaniga G et al. Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting. Leukemia 2007;21(4):706-13 doi: 10.1038/sj.leu.2404535.

Drandi D, Alcantara M, Benmaad I et al. Droplet Digital PCR Quantification of Mantle Cell Lymphoma Follow-up Samples From Four Prospective Trials of the European MCL Network. Hemasphere 2020;4(2):e347 doi: 10.1097/HS9.0000000000000347.

Brüggemann M, Reigl T, Kotrová M et al. Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia 2019;33(9):2254-2265 doi: 10.1038/ s41375-019-0499-4.

Pott C, Macintyre E, Delfau MH et al. Prediction of relapse by standardized IG-based allel-specific qPCR, ddPCR and amplicon NGS for MRD monitoring in mantle cell lymphoma: a comparative analysis by the EU-MCL network. Hematological Oncology 2021;39(S2):145-383 Supplement 16th International Conference on Malignant Lymphoma, Virtual Edition, 18–22 June, 2021 https://doi.org/10.1002/hon.2880.

© 2023 Il Pensiero Scientifico Editore

Tutti i diritti sono riservati per tutti i Paesi

Impaginazione e copertina Typo85 Srl

Immagine in copertina ©iStock by Getty Images